From The Economic Times · PTI · · 1m
Pfizer India defends patient safety after Karnataka FDA crackdown
Pfizer India says patient safety remains top priority after Karnataka FDA cancels 16 drug licenses for counterfeit medicines
In brief
Pfizer India says patient safety remains top priority after Karnataka FDA cancels 16 drug licenses for counterfeit medicines Pfizer India removed counterfeit products and cooperated with authorities following Karnataka FDA's crackdown on fake medicines. Originally reported by The Economic Times.
Pfizer India responds
Pfizer India stated patient safety and product quality are their top priorities after Karnataka FDA canceled 16 drug licenses for counterfeit medicines.
“Patient safety and product quality are of the highest priority for us at Pfizer.”
Karnataka FDA action
Karnataka health regulator canceled 16 drug licenses and suspended eight others for alleged distribution of counterfeit medicines.
Pfizer's actions
Pfizer removed counterfeit batches from the market and supported efforts to differentiate original from counterfeit products.
Counterfeit operation
Karnataka FDA busted an unlicensed repacking operation at a farmhouse in Bengaluru South district, seizing Rs 5.05 crore worth of fake drugs.
Pfizer cooperation
Pfizer has worked with authorities for one month to resolve open queries and protect patient safety.
The one thing
Pfizer India removed counterfeit products and cooperated with authorities following Karnataka FDA's crackdown on fake medicines.
